For many, the introduction of the first two vaccines against Covid-19 — one by Cambridge-based Moderna Inc. and the other by Pfizer Inc. and BioNTech SE — has signaled the beginning of the end of the pandemic. But a host of other drug companies continue to develop other preventive drugs to fight the virus, and all see a role for their products in coming months or years.
Local research institutions, like Mass Eye and Ear, and companies like Greenlight Biosciences, Translate Bio, CureVac and Novartis AG, are all hoping to get in on the action, but won’t complete their clinical trials for many months. Some say their products could be easier to distribute, without the requirement for cold storage, while others say administration could be simpler than for existing vaccines. Here’s what those local companies are saying about their products still in development for Covid.